Welcome to our dedicated page for Definium Therapeutics news (Ticker: DFTX), a resource for investors and traders seeking the latest updates and insights on Definium Therapeutics stock.
Definium Therapeutics, Inc. develops investigational therapeutics for psychiatric and neurological disorders. The company’s news centers on DT120 ODT (lysergide tartrate), its lead Phase 3 program for generalized anxiety disorder and major depressive disorder, along with clinical-trial progress, pre-commercial planning, and updates on the treatment landscape for mood and anxiety disorders.
Recurring announcements also include quarterly and annual financial results, investor and analyst events, research publications related to generalized anxiety disorder, and public-company compensation actions such as Nasdaq inducement grants for new employees.
Definium Therapeutics (NASDAQ: DFTX) announced the July 16, 2026 launch of Wired for Worry, a disease education initiative for healthcare providers focused on generalized anxiety disorder (GAD). The program offers interactive clinical resources on GAD symptoms, assessment, disease burden, and neurobiology, emphasizing evidence-based education.
According to Definium Therapeutics, Wired for Worry highlights research on dysregulated brain circuitry in GAD and promotes consistent use of the GAD-7 screening scale to improve patient identification and outcomes. The company plans to expand the platform over time with additional educational content and coverage of other psychiatric disorders.
Definium Therapeutics (Nasdaq: DFTX) reported results from a large U.S. healthcare claims study on treatment patterns in newly diagnosed and established patients with generalized anxiety disorder (GAD), published in CNS Spectrums. The analysis examined pharmacotherapy use, discontinuation, switching, and treatment progression versus guideline-recommended treatment durations.
The study found high rates of discontinuation and switching, rapid treatment changes, and prolonged gaps in care. According to Definium Therapeutics, many patients stopped or modified initial therapy well before the recommended 6–12 months, and over half of newly diagnosed patients who discontinued did not restart during follow-up, underscoring substantial unmet need in GAD.
Definium Therapeutics (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company focused on psychiatric and neurological disorders, granted inducement stock options to eight newly hired non-executive employees. The awards cover 169,740 common shares, have exercise prices equal to the July 6, 2026 closing share price, and vest over four years.
The options were approved on June 25, 2026 under NASDAQ Rule 5635(c)(4) and issued pursuant to Definium’s 2026 Inducement Plan.
Definium Therapeutics (Nasdaq: DFTX) closed an upsized underwritten public offering of 23,676,471 common shares at $34.00 per share, including the underwriters’ full option for 3,088,235 extra shares, raising $805 million gross. Proceeds will fund R&D, potential DT120 ODT commercialization preparations, and general corporate purposes.
Definium Therapeutics (Nasdaq: DFTX) priced an upsized underwritten public offering of 20,588,236 common shares at $34.00 per share, for expected gross proceeds of about $700 million, before expenses.
The company granted underwriters a 30-day option for up to 3,088,235 additional shares and plans to use proceeds for R&D, potential DT120 ODT commercialization preparation, and general corporate purposes.
Definium Therapeutics (Nasdaq: DFTX) announced a proposed underwritten public offering of $500 million in common shares and pre-funded warrants. Underwriters may receive a 30-day option to purchase up to $75 million of additional common shares.
Proceeds are intended for R&D, potential DT120 ODT commercialization preparation, and general purposes.
Definium Therapeutics (DFTX) reported positive topline results from the Phase 3 Emerge study of single-dose DT120 ODT 100 µg in adults with major depressive disorder.
The trial met its primary and all key secondary efficacy endpoints, with rapid, durable MADRS improvements and a generally favorable safety profile without serious adverse events or suicidality signal.
Definium Therapeutics (DFTX) plans a live webcast on June 22, 2026, at 8:00 a.m. EDT to discuss topline results from Emerge, its first randomized, double-blind, placebo-controlled Phase 3 study of a single 100 µg dose of DT120 ODT in adults with major depressive disorder.
The webcast replay will be available in the Investor Relations section of the company website for at least 30 days.
Definium Therapeutics (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company focused on psychiatric and neurological disorders, granted inducement stock options to six newly hired non-executive employees effective June 15, 2026.
The grants cover 155,480 common shares, have an exercise price equal to the grant-date closing share price, vest over four years, were approved under NASDAQ Rule 5635(c)(4), and were issued outside existing equity incentive plans.
Definium Therapeutics (NASDAQ:DFTX) granted inducement equity awards to thirteen newly hired non-executive employees. The awards comprise options to purchase an aggregate of 462,190 common shares, granted on May 18, 2026 and June 1, 2026, with exercise prices set at each grant date’s closing share price.
The options vest over four years: 25% on the first anniversary, then 75% in equal monthly installments over the next three years, subject to continued employment. According to Definium, the grants were approved by the Compensation Committee under Nasdaq Rule 5635(c)(4) as material inducements to employment and were issued outside existing equity incentive plans.